DAVID
BERNARDO ORDIZ
PROFESORA SUSTITUTA/PROFESOR SUSTITUTO
![Foto de María](/img/nophoto.png)
María
Chaparro Sánchez
Publicaciones en las que colabora con María Chaparro Sánchez (11)
2024
-
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients
Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182
2022
2020
-
Serum adipokines as non-invasive biomarkers in Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
-
Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU
Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428
-
Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 13, Núm. 11, pp. 1380-1386
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2018
-
Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases
Molecular Nutrition and Food Research, Vol. 62, Núm. 7
-
Human intestinal pro-inflammatory CD11chighCCR2+CX3CR1+ macrophages, but not their tolerogenic CD11c-CCR2-CX3CR1- counterparts, are expanded in inflammatory bowel disease article
Mucosal Immunology, Vol. 11, Núm. 4, pp. 1114-1126